검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | therapeutic autologous dendritic cells (therapeutic autologous dendritic cells) Susan G. Komen Breast Cancer Found…·Breast Cancer 32 trials |
|---|---|
Overview Program | therapeutic autologous dendritic cells |
Overview Company | Susan G. Komen Breast Cancer Foundation |
Overview Modality | ANTIBODY |
Overview Target | Breast Cancer |
Overview Indication | Stage III Hepatocellular Carcinoma AJCC v8; Stage III Intrahepatic Cholangiocarcinoma AJCC v8 |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | targeting a human tumor-specific antigen |
MoA Biomarker | biomarker analysis of a placebo-controlled phase 2b trial |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | REACtiVe-2: phase I evaluation of dendritic cell vaccination and agonistic CD40 therapy following (m)FOLFIRINOX in metastatic pancreatic cancer.. In pancreatic ductal adenocarcinoma (PDAC), the dense desmoplastic stroma and insufficient infiltrating T cells represent a significant barrier to effective immunotherapy. In this phase I, dose-escalation study, previously registered at the Dutch Trial R… |
Toxicology CRS | Reported |
Clinical Data Tier / Score | A · 32 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | therapeutic autologous dendritic cells (therapeutic autologous dendritic cells) Susan G. Komen Breast Cancer Found…·Breast Cancer 32 trials |
|---|---|
Overview Program | therapeutic autologous dendritic cells |
Overview Company | Susan G. Komen Breast Cancer Foundation |
Overview Modality | ANTIBODY |
Overview Target | Breast Cancer |
Overview Indication | Stage III Hepatocellular Carcinoma AJCC v8; Stage III Intrahepatic Cholangiocarcinoma AJCC v8 |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | targeting a human tumor-specific antigen |
MoA Biomarker | biomarker analysis of a placebo-controlled phase 2b trial |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | REACtiVe-2: phase I evaluation of dendritic cell vaccination and agonistic CD40 therapy following (m)FOLFIRINOX in metastatic pancreatic cancer.. In pancreatic ductal adenocarcinoma (PDAC), the dense desmoplastic stroma and insufficient infiltrating T cells represent a significant barrier to effective immunotherapy. In this phase I, dose-escalation study, previously registered at the Dutch Trial R… |
Toxicology CRS | Reported |
Clinical Data Tier / Score | A · 32 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교